CN115843268A - 治疗性MuSK抗体 - Google Patents

治疗性MuSK抗体 Download PDF

Info

Publication number
CN115843268A
CN115843268A CN202180035285.0A CN202180035285A CN115843268A CN 115843268 A CN115843268 A CN 115843268A CN 202180035285 A CN202180035285 A CN 202180035285A CN 115843268 A CN115843268 A CN 115843268A
Authority
CN
China
Prior art keywords
seq
cdr
chain variable
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035285.0A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·J·布尔登
小出祥平
小出明子
纳迪娅·勒卢
朱利恩·乌里
卡伦·西伦斯
鲁兰·瓦努瓦特
克里斯托弗·布朗什托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agence Co ltd
New York University NYU
Original Assignee
Arkinx Iip Co ltd
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkinx Iip Co ltd, New York University NYU filed Critical Arkinx Iip Co ltd
Publication of CN115843268A publication Critical patent/CN115843268A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180035285.0A 2020-04-17 2021-04-16 治疗性MuSK抗体 Pending CN115843268A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011986P 2020-04-17 2020-04-17
US63/011,986 2020-04-17
US202063038633P 2020-06-12 2020-06-12
US63/038,633 2020-06-12
US202063112375P 2020-11-11 2020-11-11
US63/112,375 2020-11-11
PCT/US2021/027801 WO2021212053A2 (en) 2020-04-17 2021-04-16 Therapeutic musk antibodies

Publications (1)

Publication Number Publication Date
CN115843268A true CN115843268A (zh) 2023-03-24

Family

ID=75850676

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035285.0A Pending CN115843268A (zh) 2020-04-17 2021-04-16 治疗性MuSK抗体

Country Status (12)

Country Link
US (2) US11492401B2 (https=)
EP (1) EP4136115A2 (https=)
JP (2) JP7772715B2 (https=)
KR (1) KR20230028217A (https=)
CN (1) CN115843268A (https=)
AU (1) AU2021256049A1 (https=)
BR (1) BR112022021065A2 (https=)
CA (1) CA3175597A1 (https=)
IL (1) IL297295A (https=)
MX (1) MX2022011856A (https=)
PH (1) PH12022552483A1 (https=)
WO (1) WO2021212053A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147489A2 (en) * 2022-01-28 2023-08-03 argenx BV Anti-musk antibodies for use in treating neuromuscular disorders
WO2023218099A1 (en) * 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
AU2024271522A1 (en) * 2023-05-15 2025-11-20 argenx BV Antibodies for use in agrin-deficient disorders
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150050289A1 (en) * 2011-11-14 2015-02-19 New York University Muscle specific receptor kinase and modulation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6737249B1 (en) 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US6624819B1 (en) 2000-05-01 2003-09-23 Broadcom Corporation Method and system for providing a flexible and efficient processor for use in a graphics processing system
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2453822C (en) 2001-08-03 2011-02-22 Tyco Healthcare Group Lp Tissue marking apparatus and method
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
JP2011207769A (ja) 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
US9574015B2 (en) 2013-09-13 2017-02-21 New York University Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150050289A1 (en) * 2011-11-14 2015-02-19 New York University Muscle specific receptor kinase and modulation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANTOR S等: "Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody", ELIFE, vol. 7, 20 February 2018 (2018-02-20), pages 1 - 19 *

Also Published As

Publication number Publication date
AU2021256049A1 (en) 2022-11-03
BR112022021065A2 (pt) 2023-02-23
JP2026056615A (ja) 2026-04-01
IL297295A (en) 2022-12-01
PH12022552483A1 (en) 2024-02-05
JP7772715B2 (ja) 2025-11-18
US11492401B2 (en) 2022-11-08
US20220259304A1 (en) 2022-08-18
WO2021212053A3 (en) 2021-11-18
WO2021212053A8 (en) 2022-09-29
MX2022011856A (es) 2023-02-23
WO2021212053A2 (en) 2021-10-21
JP2023522212A (ja) 2023-05-29
CA3175597A1 (en) 2021-10-21
KR20230028217A (ko) 2023-02-28
US20230151091A1 (en) 2023-05-18
EP4136115A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
US10875910B2 (en) Antibodies recognizing alpha-synuclein
JP7772715B2 (ja) 治療用ｍｕｓｋ抗体
EP2084190B1 (en) Lingo binding molecules and pharmaceutical use thereof
JP6744856B2 (ja) α−シヌクレインを認識する抗体を含む血液脳関門シャトル
JP2018148911A (ja) α−シヌクレインを認識するヒト化抗体
US12365724B2 (en) Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
CN118995907A (zh) 抗序列相似家族19成员a5抗体用于治疗和诊断情绪障碍的用途
US20250051477A1 (en) Anti-musk antibodies for use in treating neuromuscular disorders
WO2023218099A1 (en) In utero treatment of a fetus having genetic disease/neuromuscular disease
US20250188190A1 (en) In utero treatment of a fetus having genetic disease/neuromuscular disease
HK40091546A (zh) 治疗性musk抗体
EA051806B1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ MuSK
WO2024235870A1 (en) Antibodies for use in agrin-deficient disorders
HK40112910A (zh) 用於治疗神经肌肉病症的抗musk抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: USA New York

Applicant after: NEW YORK University

Applicant after: Agnes Benelux Ltd.

Address before: USA New York

Applicant before: NEW YORK University

Applicant before: Arkinx IIP Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230710

Address after: USA New York

Applicant after: NEW YORK University

Applicant after: Agence Co.,Ltd.

Address before: USA New York

Applicant before: NEW YORK University

Applicant before: Agnes Benelux Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091546

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Steven J. Bourdon

Inventor after: Catherine. Maurice

Inventor after: Bernhardt Van Kelk Hoffen

Inventor after: Xiao Beixiangping

Inventor after: Akiko Kobayashi

Inventor after: Nadia Lelu

Inventor after: Julian Uri

Inventor after: SILENCE KAREN

Inventor after: Rulan Vanuat

Inventor after: Christopher Blancheto

Inventor after: Christopher Steyaert

Inventor before: Steven J. Bourdon

Inventor before: Xiao Beixiangping

Inventor before: Akiko Kobayashi

Inventor before: Nadia Lelu

Inventor before: Julian Uri

Inventor before: SILENCE KAREN

Inventor before: Rulan Vanuat

Inventor before: Christopher Blancheto